Oncology Xagena
The results from the Phase III REGARD trial of Ramucirumab as a single agent in patients with advanced gastric cancer who have had disease progression after initial chemotherapy were published in The ...
Vascular endothelial growth factor ( VEGF ) and VEGF receptor-2 ( VEGFR-2 )-mediated signalling and angiogenesis can contribute to the pathogenesis and progression of gastric cancer.The aim of a study ...
Vascular endothelial growth factor ( VEGF ) and VEGF receptor-2 ( VEGFR-2 )-mediated signalling and angiogenesis can contribute to the pathogenesis and progression of gastric cancer. A study has asse ...
